IL-12\textsuperscript{hi} Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ–Dependent Apoptosis of Alloreactive CD4\textsuperscript{+} T Cells In Vitro and Reduce Lethal Graft-Versus-Host Disease

Elizabeth O. Stenger\textsuperscript{1,5}, Brian R. Rosborough\textsuperscript{1,2,3}, Lisa R. Mathews\textsuperscript{1,2}, Huihui Ma\textsuperscript{4}, Markus Y. Mapara\textsuperscript{4}, Angus W. Thomson\textsuperscript{1,2,3}, Heth R. Turnquist\textsuperscript{1,2,3,*}

\textsuperscript{1}Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
\textsuperscript{2}Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
\textsuperscript{3}Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
\textsuperscript{4}Division of Hematology/Oncology, Department of Medicine, Hematologic Malignancies Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
\textsuperscript{5}Division of Pediatric Hematology/Oncology, Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

A B S T R A C T

Rapamycin (RAPA) inhibits the mechanistic target of rapamycin (mTOR), a crucial immune system regulator. Dendritic cells (DCs) generated in RAPA (RAPA-DC) enrich for CD4\textsuperscript{+} for the generation of IFN-γ–dependent alloreactive CD4\textsuperscript{+} T cells. However, IFN-γ is pro-apoptotic and IL-12–driven IFN-γ inhibits experimental graft-versus-host disease (GVHD). We hypothesized that IL-12\textsuperscript{hi} RAPA-DC would facilitate IFN-γ–mediated apoptosis of alloreactive T cells in culture, and unlike control (CTR)-DC, would reduce lethal GVHD. Following LPS stimulation, RAPA-DC exhibited decreased IFN-γ and IL-12, and we associated with increased expression of Fas and cleaved caspase 8. DC production or responses to IFN-γ were not important to increased apoptotic functions of RAPA-DC. LPS-stimulated IL-12\textsuperscript{hi} RAPA-DC is a probable mechanism underlying the capacity of LPS-treated RAPA-DC to reduce GVHD.

INTRODUCTION

Dendritic cells (DCs) are important bone marrow–derived professional antigen-presenting cells that induce and regulate T cell responses [1-4]. This dichotomy reflects DC phenotypic and functional plasticity. Immature DCs (MHCII\textsuperscript{lo}CD86\textsuperscript{lo}) display inherent tolerogenicity, whereas mature DCs (MHCII\textsuperscript{hi} CD86\textsuperscript{hi}) are potent inducers of adaptive immunity. Numerous immunosuppressive and anti-inflammatory agents inhibit DC maturation and promote their tolerogenicity in vitro and in vivo [3,5].

Rapamycin (RAPA) inhibits the serine/threonine kinase mechanistic target of rapamycin (mTOR), a crucial immune response regulator that integrates environmental signals leading to cell growth and proliferation [6]. DCs generated in clinically relevant concentrations of RAPA (RAPA-DCs), either in vivo or in vitro, are immature and fail to mature phenotypically (fully up-regulate MHCII and CD86) [7-12]. They induce apoptosis of polyclonal allogeneic T cells (referred to hereafter as alloreactive T cells) and enrich for CD4\textsuperscript{+}FoxP3\textsuperscript{+} T cells [9,12]. Alloantigen–presenting autologous RAPA-DCs promote experimental organ allograft survival, inhibit graft-versus-host disease (GVHD), and reduce dependence on post-transplant immunosuppression [9,13].

Paradoxically, mTOR inhibitors cause a dysregulation of cytokine production by DCs upon their exposure to pro-inflammatory stimuli [11,14,15]. Of particular significance, costimulatory molecule–low (CD86\textsuperscript{lo}), lipopolysaccharide (LPS)-stimulated RAPA-DCs secrete increased IL-12 [11,16], a classical immunostimulatory cytokine that drives T helper type 1 cell responses. However, both IL-12p40 and IL-12 (R) have been shown to be integral to the de novo induction of regulatory T cells (Treg) [11,17]. In addition, IFN-γ is required for activation-induced T cell death via caspase 8 [18], Fas-dependent apoptosis of donor CD4\textsuperscript{+} T cells in experimental GVHD [19], and the induction and function of Treg [20,21]. Significantly, administration of IL-12 inhibits experimental GVHD, dependent on IFN-γ–mediated donor

Financial disclosure: See Acknowledgments on page 200

*Correspondence and reprint requests: Heth R. Turnquist, PhD, Starzl Transplantation Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, E1554 BST, Pittsburgh, PA 15261.
E-mail address: hrt@pitt.edu (H.R. Turnquist).

© 2014 American Society for Blood and Marrow Transplantation.
T cell apoptosis, yet preserves important IFN-γ–dependent graft-versus-leukemia (GVL) effects [22–24]. Based on promising anti-tumor effects in experimental animal models, phase I and II trials of systemic IL-12 were undertaken in renal cell carcinoma, but excessive morbidity and mortality halted further investigation [25]. Thus, harnessing the therapeutic capacity of IL-12 for the prevention of GVHD [22–24] will require novel treatments without systemic, potentially toxic side effects.

Given our previous demonstration of an increased capacity of RAPA-DCs to support alloreactive T cell apoptosis [9,12], we aimed to determine if augmented IL-12 production by costimulatory molecule poor RAPA-DCs would mediate apoptosis of CD4+ T cells through IFN-γ. Further, based on the reported inhibitory effects of both RAPA-DCs [13] and IL-12 in experimental GVHD [22–24], we completed limited investigations into the therapeutic capacity of IL-12hi RAPA-DCs in an experimental model of GVHD, where we hypothesized they would have augmented capacity to reduce lethal GVH.

**METHODS**

**Animals**

Wild-type C57BL/6j (B6; H2Kb), BALB/c (H2Kd), B6, 129S7 (I-Ab+B22.2), and B6,129S7 (I-Ab+B22.2) (SJL/J) (IFN-γ−/−; I-Ab+B22.2) and B6.129S7 (I-Ab+B22.2) (FVB/N) DCs were used for positive selection (purity > 90%).

**Mixed Leukocyte Reactions**

BALB/c, B6, or IFN-γ−/− (BALB/c) bulk CD4+ T cells were isolated from spleens as described [30]. Briefly, splenic T cells were purified by negative selection of non-T cells using anti-CD11b, -TER-119, -Gr-1, -I-A/I-E, -B220, and -Gr-1 mAb (BD Pharmingen; San Jose, CA, US) and were removed via Mouse Depletion Dynabeads (Dynal Biotech, Grand Island, NY). B6, IFN-γ−/− (B6), or IL-12p40−/− (B6) CD11c+ DCs were used as stimulators of purified allogeneic CD4+ T cells in 5-day (unless otherwise indicated) mixed leukocyte reactions (MLRs) at a 1:10 ratio in 96-well, round-bottom plates, with or without anti-IFN-γ mAb added on day 1 (1.0 mg/mL, XMG1.2; PharMingen). T cells were also examined for cell surface CD4 and Fas (CD95) expression using 7-AAD (eBiosciences; San Diego, CA, US).

**Flow Cytometry**

DCs were analyzed for intracellular expression of IL-12 and for cell surface expression of CD11c, IAα, CD80, CD86, CD80, CD8a, CD4, and B220 using fluorochrome-conjugated mAb (BD Biosciences or eBioscience). T cell apoptosis was quantified using an Annexin V–PE Apoptosis Detection kit (BD Pharmingen). T cells were also examined for cell surface CD4 and Fas (CD95) and for intracellular IFN-γ expression using fluorochrome-conjugated mAb (BD Biosciences or eBioscience). Intracellular expression of cleaved caspase 8 was assessed using primary rabbit mAb (Cell Signaling, Danvers, MA; 9746S) followed by fluorochrome-conjugated anti-rabbit mAb (A131573; Invitrogen, Grand Island, NY). Isotype-matched IgGs were used as controls. An LSR II or LSR Fortessa (BD Biosciences, San Jose, CA) was used for data acquisition and data analyzed using FlowJo (TreeStar, version 8.8.7, Ashland, OR).

**Allogeneic Bone Marrow Transplantation and Induction of Lethal GVHD**

The capacity of syngeneic DCs to limit GVHD was assessed in lethally irradiated (800 cGy) female BALB/c recipients reconstituted with 5 × 106 T cell-depleted B6 bone marrow cells on day 0. CD902 microbeads (Miltenyi Biotec) were used for T cell depletion according to the manufacturer’s recommendations. Recipient mice were given 1 × 106 CD11c+ BALB/c DC (control [CTR]), RAPA, or RAPA-DCs exposed to LPS) and 1 × 106 B6 pan T cells on day 1. Pan T cells were isolated from spleens by negative selection using the Pan T Isolation Kit (Miltenyi Biotec) according to the manufacturer’s instructions. Mice in each group were allocated randomly to different cages to minimize cage-related effects. They received antibiotic water (trimethoprim-sulfamethoxazole; Hi-Tech Pharmeval, Amelia, NJ, US) from day −7 through day +14.

**Clinical GVHD Evaluation**

Mice were assessed for GVHD morbidity using a standard scoring system [27] based on weight loss, posture, activity level, fur texture, and integrity of skin. The animals were monitored every other day (or more frequently if indicated), and mice with >20% body weight loss were killed.

**Statistical Analyses**

Results from pooled completed experiments are expressed as means ± standard deviation (SD) or standard error. The significances of differences between means were determined using Student’s t-test with P < 0.05 considered as significant. Survival curves were generated using GraphPad Prism 2.0C Software package (GraphPad Software, Inc., La Jolla, CA) with differences in survival determined by Kaplan-Meier analysis and the log-rank test.

**RESULTS**

**Costimulatory Molecule-Low, LPS-Stimulated RAPA-DCs Express High Levels of IL-12 and Induce Apoptosis of Alloreactive CD4+ T Cells via an IFN-γ-Dependent Mechanism In Vitro**

By conventional phenotyping, CD11c+ RAPA-DCs were very similar to CTR-DCs and displayed a phenotype consistent with conventional myeloid derived DCs (Supplemental Figure 1). Compatible with our previous data [11], RAPA-DCs displayed significantly reduced costimulatory molecule (CD86) expression (representative and aggregate data; Figure 1A,B) compared with CTR-DCs. RAPA-DCs also significantly down-regulated IAα and CD80 (Supplemental Figure 2). After LPS stimulation, CTR-DCs expressing IL-12p40 displayed high levels of CD86, where RAPA-DCs retained lower levels of CD86 but still up-regulated IL-12p40 expression (Figure 1A,B). Thus, RAPA-DCs after exposure to LPS displayed a dominant population of CD86hiIL-12hi cells (Figure 1A,B). We demonstrated previously a direct correlation between intracellular IL-12 expression and secretion of IL-12 by mTOR-inhibited DCs [11,16]. RAPA-DCs from IL-12p40−/− mice also displayed reduced CD86 levels compared with CTR IL-12p40+ DCs, both before and after LPS exposure. This suggests that an IL-12-independent regulatory mechanism suppresses CD86 expression on RAPA-DCs.

We demonstrated previously [9] that unstimulated or CD40-ligated RAPA-DCs induce increased apoptosis (Annexin V−7–AAD−) of wild-type alloreactive CD4+ T cells in 5-day MLRs compared with CTR-DC counterparts. Our present data (Figure 1C,D) confirm the increased capacity of unstimulated RAPA-DCs to induce apoptosis when used as stimulators (12.7% ± 2.3% versus 7.3% ± 4%; P < 0.05). Importantly, we also now show that LPS-stimulated IL-12hi RAPA-DCs induce significantly more apoptosis compared with CTR-DCs (RAPA + LPS: 28.5% ± 4.4% versus 15.4% ± 2.9%; P < 0.05) (Figure 1C, representative data; Figure 1D, average across 3 experiments normalized to CTR). IL-12p70 is the principal inducer of IFN-γ production by immune cells, especially CD4+ T cells [28]. However, even while supporting T helper type 1 responses, IFN-γ is necessary for activation-induced cell death of T-cell receptor-stimulated T cells [18]. LPS-stimulated RAPA-DCs induced augmented apoptosis of allogeneic CD4+ T cells (Figure 1). Given that...
IL-12 released by antigen presenting cells stimulates IFN-γ production by CD4+ T cells [29], we investigated the role of IFN-γ in the pro-apoptotic function of RAPA-DCs using neutralizing Abs. The apoptosis of allogeneic CD4+ T cell induced by LPS-stimulated IL-12hi RAPA-DCs was decreased significantly when IFN-γ was blocked via anti-IFN-γ mAb (Figure 1C,D). In fact, with anti-IFN-γ mAb added to LPS-stimulated RAPA-DC cultures, the degree of apoptosis was reduced to levels similar to those induced by LPS-stimulated CTR-DCs (18.7% ± 1.0% versus 15.4% ± 2.9%; NS). Thus, apoptosis of allogeneic CD4+ T cells promoted by RAPA-DC in vitro is mediated, at least in part, by IFN-γ, a cytokine driven by IL-12 that is expressed at high levels by RAPA-DC in vitro is mediated, at least in part, by IFN-γ.

**IL-12hi RAPA-DCs Induce Increased Production of IFN-γ by CD4+ T Cells**

Given that apoptosis of CD4+ T cells driven by IL-12hi RAPA-DC is dependent on IFN-γ, we next sought to determine which cells were producing IFN-γ. IFN-γ expression was not detected in the supernatants of any DC groups by ELISA (CTR ± LPS or RAPA ± LPS; data not shown). As reported previously [11], production of IFN-γ by CD4+ T cells was not altered when assessed on day 5 of MLR with LPS-stimulated RAPA-DCs. Therefore, we analyzed IFN-γ production at earlier time points during MLRs (day 1 and day 2). As shown in Figure 2, both unstimulated RAPA-DCs and LPS-stimulated RAPA-DCs induced increased IFN-γ production by CD4+ T cells compared with CTR groups (day 1: 3.2 ± 8 versus 10.6 ± 9; LPS: 6.1 ± 12 versus 10.6 ± 2.1; P < 0.05; day 2: 3.6 ± 2.1 versus 10.5 ± 5.9; LPS: 6.0 ± 3.1 versus 10.1 ± 3.4; P < 0.05) (Figure 2A representative data, Figure 2B average across 3 experiments normalized to CTR). Therefore, IL-12hi RAPA-DC promote apoptosis of allogeneic CD4+ T cells via induction of IFN-γ by the T cells, not the DCs.

**Apoptosis of Alloreactive CD4+ T Cells Induced by LPS-Exposed IL-12hi RAPA-DCs Depends on T Cell But Not DC Responses to IFN-γ**

Using a neutralizing Ab, we determined that IFN-γ was an important mediator of the increased apoptosis of allogeneic CD4+ T cells induced by LPS-stimulated RAPA-DCs. Next, we performed studies to determine whether IFN-γ was acting in this capacity on DCs, CD4+ T cells, or both. When exposed to LPS-stimulated IL-12hi RAPA-DCs, IFN-γ-R−/− CD4+ T cells exhibited decreased apoptosis (Annexin V−7-AAD−) in 5-day
MLRs when compared with wild-type CD4^+ T cells (5.5% ± 1.9% versus IFN-γ^-/- 6.4% ± 3.1%; +LPS: 15.6% ± 3.6% versus 4.9% ± 1.1%; P < .05 for LPS) (Figure 3A representative data; Figure 3B average across 2 experiments normalized to CTR). Unlike those of CD4^-/- T cells, DC responses to IFN-γ were not important in mediating the function of RAPA-DCs (Figure 3C representative data; Figure 3D average across 2 experiments normalized to CTR). There was no difference in the extent of apoptosis of alloreactive CD4^+ T cells induced by IFN-γ^-/- RAPA-DCs compared with wild-type RAPA-DCs (12.4% ± 7.6% versus 10.5% ± 7.6% respectively; +LPS: 27.2% ± 11.9% versus 30.1% ± 16.3%; both NS; Figure 3). The addition of anti-IFN-γ mAb to LPS-stimulated IFN-γ^-/- RAPA-DCs significantly decreased levels of CD4^+ T cell apoptosis similar to LPS-stimulated wild-type CTR-DCs (18.0% ± 10.3% versus 21.9% ± 6.3%; P = NS; Figure 3D). These data strongly support the conclusion that IFN-γ mediates increased apoptosis of alloreactive T cells directly and not through actions on DCs.

**Induction of Apoptosis by LPS-Stimulated RAPA-DCs Depends on IL-12 Expression**

Using IL-12p40^-/- DCs, we next explored the role of DC IL-12 expression in the increased apoptosis of CD4^+ T cells induced by RAPA-DC. As shown in Figure 4, LPS-stimulated IL-12p40^-/- RAPA-DCs induced lower levels of apoptosis in 5-day MLRs, defined by Annexin V^+ 7-AAD^- T cells, compared with wild-type DC (16.9% ± 8.9% versus 20.8% ± 10.0%; P < .05) (Figure 4A representative data; Figure 4B average across 3 experiments normalized to CTR LPS). The addition of anti-IFN-γ to MLRs further decreased apoptosis of alloreactive CD4^+ T cells induced by LPS-stimulated IL-12p40^-/- RAPA-DCs (12.0% ± 6.1% versus 16.9% ± 8.9%; P < .05).

**CD4^+ T Cells Interacting with IL-12^hi RAPA-DCs Exhibit Increased Fas and Cleaved Caspase 8**

Based on the importance of the Fas pathway in IFN-γ-dependent activation-induced cell death and apoptosis of donor CD4^+ T cells in experimental GVHD [18,19], we assessed if either the Fas receptor or the downstream pro-apoptotic effector caspase 8 is modulated on CD4^+ T cells after 1 and 2 days co-culture with RAPA-DCs. Both unstimulated and LPS-stimulated RAPA-DCs enhanced the expression of Fas on CD4^+ T cells compared with their respective CTR-DC counterparts, particularly after a 1-day exposure (day 1: 3.3 ± .8 versus 1.3 ± .6, LPS: 7.1 ± 1.4 versus 3.5 ± 1.0, P < .05; day 2: 4.1 ± 1.5 versus 1.9 ± 1.5, P < .05; LPS: 6.6 ± 2.4 versus 3.1 ± 1.6, P = .05) (Figure 5A representative data; Figure 5B average across 3 experiments normalized to CTR). Compared with CTR-DCs, RAPA-DCs stimulated increased expression of cleaved caspase 8 in CD4^+ T cells, particularly after a 2-day co-culture (day 1: 14.2 ± 5.3 versus 9.2 ± 4.7, P < .05; LPS: 14.2 ± 2.4 versus 10.6 ± 4.0, P > .05; day 2: 11.4 ± 5.6 versus 6.2 ± 3.9, P < .05; LPS: 10.9 ± 6.6 versus 8.7 ± 4.2, P > .05) (Figure 5C representative data;
compared with wild-type (12.4% versus IFN-γ-R−/− cells have decreased levels of apoptosis (Annexin V−7-AAD−) compared with wild-type T cells after exposure to LPS-treated IL-12hi RAPA-DCs (wild-type 5.5% ± 1.9% versus IFN-γ-R−/− 6.4% ± 3.1%, +LPS: 15.6% ± 3.6% versus 4.9% ± 1.1%, P < .05 for LPS). (B) Average fold increase in CD4+ Annexin V−7-AAD− cells relative to CTR-DCs on day 5 of MLRs. Error bars indicate mean ± 1 SD. n = 2. *P < .05. (C) IFN-γ-R−/− IL-12hi RAPA-DCs induce similar apoptosis (Annexin V−7-AAD−) of CD4+ T cells compared with wild-type (12.4% ± 7.6% versus 10.5% ± 7.6%, respectively; +LPS: 27.2% ± 11.9% versus 30.1% ± 16.3%, both NS). However, blocking IFN-γ significantly decreased apoptosis induced by LPS-stimulated IFN-γ-R−/− RAPA-DCs to levels similar to LPS-stimulated wild-type CTR-DCs (18.0% ± 10.3% versus 21.9% ± 6.3%, P = NS). (D) Average fold increase in CD4+ Annexin V−7-AAD− cells relative to wild-type CTR-DCs on day 5 of MLRs. Error bars indicate mean ± 1 SD. n = 2. *P < .05.

Autologous BALB/c DCs (CTR-DCs ± LPS or RAPA-DCs ± LPS) were administered as negative cellular vaccines at the time of bone marrow transplantation, in a fully MHC-mismatched model of acute lethal GVHD (B6→BALB/c). Host IL-12hi RAPA-DC significantly prolonged host survival (median survival in days: GVHD, 17.5 days; RAPA-DCs, 25 days, P = .007; syngeneic control, >50 days, P = .002) (Figure 6C). In contrast, mice given CTR-DCs ± LPS had similar GVHD mortality to untreated control mice (CTR-DCs: 8 days; LPS→CTR-DCs: 11 days, both P = NS). These data demonstrate that syngeneic LPS-stimulated RAPA-DCs can prolong survival from GVHD when given as a negative cellular vaccine.

DISCUSSION

DCs are of critical importance in determining the balance between immunity and tolerance [31], and numerous studies have demonstrated the in vitro generation of tolerogenic (tol)DCs with potent modulating effects on autoimmunity [32] and allograft rejection [3,4,33,34]. TolDCs resemble
quiescent or “immature” DCs in vivo, which under steady-state, noninflammatory conditions express low levels of surface MHC and costimulatory molecules (eg, CD40, CD80, CD86) [1,3]. Both tolDCs and immature DCs can induce unresponsiveness, or anergy, and apoptosis in naïve T cells, support Treg, and inactivate/delete memory and effector CD8\(^+\) T cells [3,4]. However, DC immaturity is not fixed, and the sensing of danger signals by DCs triggers signaling pathways that direct DC “maturation” [1]. Mature DCs have increased T cell-stimulatory capacity through augmented surface expression of MHC and costimulatory molecules, particularly CD86. Likewise, different stimuli trigger receptors on DCs to launch the appropriate production of cytokines needed to facilitate differentiation of naïve CD4\(^+\) T cells [35]. These receptors, including the well-described TLR family, detect local “danger,” including exogenous pathogens via recognition of pathogen-associated molecular patterns and tissue damage sensed via damage-associated molecular patterns. Damage-associated molecular pattern or pathogen-associated molecular pattern triggering of most TLRs, especially TLR4, results in DC secretion of IL-12p70, a cytokine needed for naïve CD4\(^+\) T cell differentiation to IFN-γ-secreting T helper type 1 cells [36].

Many signaling pathways activated by danger signals are integrated by mTOR, which functions in at least 2 intracellular complexes to correlate appropriate cell growth/proliferation and movement with signals arising from environmental stimuli (ie, growth factors, cytokines, TLR ligands, etc.) and internal cellular conditions (ie, levels of adenosine triphosphate, arachidonic acid, or oxygen) [6]. RAPA potently inhibits mTOR, and DCs exposed to RAPA have shown promise as tolDC, specifically promoting experimental organ allograft survival, inhibiting GVHD, and reducing the need for continued post-transplant immunosuppression [9,13]. Both in vitro and in vivo, exposure to RAPA suppresses DC generation, phenotypic maturation, and T cell stimulatory function [6,9-11,26]. Also consistent with tolerogenic functions, RAPA-DCs induce alloreactive T cell anergy [26] and apoptosis [9,12] while enriching for Treg in vitro and in vivo [9,11,16]. However, when exposed to inflammatory stimuli, although RAPA-DCs fail to fully up-regulate costimulatory molecule (CD86) expression and remain poorly stimulatory, paradoxically,
they exhibit dysregulation of cytokine production, including enhanced inflammatory IL-12 production and reduced IL-10 [11,14,37]. We have shown that this enhanced IL-12p70 production results from RAPA blocking mTOR inhibition of glycogen synthase kinase-3β after TLR4 ligation [11].

Current knowledge suggests that IL-12hi DCs would act as potent generators of IFN-γ production by CD4+ cells [38]. Likewise, RAPA-enhanced IL-12 expression by DCs has been hypothesized to underlie recent reports of mTOR inhibition facilitating T cell responses to pathogens [39,40] and the occurrence, in a subset of RAPA-treated transplant patients, of inflammatory disorders, including interstitial pneumonitis [41] and glomerulonephritis [42]. However, post-transplant RAPA fails to enhance donor-specific T cell responses, even during concurrent infection [43]. Clinically, mTOR inhibition is typically associated with increased or maintained levels of in Foxp3+ T cells, unlike calcineurin inhibitors, which decrease Foxp3+ T cell incidence [44,45]. Likewise, as shown in Figure 1A, augmented IL-12p40 expression by LPS-exposed RAPA-DCs is dominated by a poorly stimulatory, co-stimulatory molecule-low (CD86lo) subset [11]. Importantly, we now establish that increased IL-12 production by RAPA-DCs supports IFN-γ-mediated apoptosis in vitro (Figure 4), and we have observed previously that IL-12p70 supports Treg induction [11].

In the present study, although IFN-γ was crucial to the increased apoptosis induced by RAPA-DCs relative to CTRL-DCs after their exposure to LPS, we did not observe that blocking IFN-γ significantly modulated the incidence of Treg (data not shown). Given the growing use of mTOR inhibitors in both transplantation and other medical areas, it will be important to continue to establish how RAPA-mediated modulation of cytokines, such as IL-12 and IL-10, impact alloimmunity and transplant survival in relevant experimental models.

Our current findings also provide new insight into the mechanisms by which RAPA-DCs promote apoptosis of alloreactive CD4+ T cells [9]. Specifically, we reveal that RAPA-DC-mediated apoptosis of alloreactive CD4+ T cells is IFN-γ-dependent and that the IFN-γ-dependent effects are the result of IFN-γ produced by T cells that interact with RAPA-DCs. Our current studies also demonstrate that this effect is mediated through IFN-γ action on CD4+ T cells and involves their increased expression of Fas and cleaved caspase 8. However, we find that the ability of IFN-γ to drive apoptosis is not due to its capacity to increase DC expression.

Figure 5. Apoptosis of CD4+ T cells by induced IL-12hi RAPA-DCs is dependent on the Fas/FasL pathway and caspase 8. B6 were generated and then used in 1- or 2-day MLRs to stimulate BALB/c CD4+ T cells. Plots are representative of 3 to 4 independent experiments performed (n = 4 for 2-day MLRs for caspase 8). (A) After exposure to IL-12hi RAPA-DCs, CD4+ T cells increased expression of Fas compared with LPS-stimulated CTRL-DCs, particularly after a 1-day exposure (day 1: 7.1 ± 1.4 versus 3.5 ± 1.0, P < .05; day 2: 6.6 ± 3.1 versus 3.1 ± 1.6, P < .05). (B) Average fold increase in CD4+ Fas+ cells relative to wild-type CTRL-DCs on day 1 or 2 of MLRs. Error bars indicate mean ± 1 SD. n = 3 (1 day) or 4 (2 day). *P < .05. (C) CD4+ T cells also up-regulate cleaved caspase 8 expression after exposure to IL-12hi RAPA-DC compared with CTRL-DCs, particularly after a 2-day MLR exposure (day 1: 14.2 ± 2.4 versus 9.2 ± 4.7, P < .05; day 2: 10.9 ± 6.6 versus 6.2 ± 3.9, P < .05). (D) Average fold increase in CD4+ cleaved caspase 8+ cells relative to wild-type CTRL-DCs on day 1 or 2 of MLRs. Error bars indicate mean ± 1 SD. n = 3 (1 day) or 4 (2 day). *P < .05.
of indoleamine 2,3-dioxygenase (data not shown), which causes local tryptophan depletion and release of kynurenines that cause caspase 8 cleavage and T cell apoptosis [46,47]. Further studies are required to determine whether the CD4⁺ T cell apoptosis induced by IL-12hi RAPA-DCs is also dependent on other cytokines dysregulated by mTOR inhibition or on the low costimulatory molecule expression by these cells.

Based on work by Sykes and colleagues [19,22-24] demonstrating inhibition of experimental GVHD with IL-12, we hypothesized that IL-12hi RAPA-DCs could provide a novel approach to harness the immunoregulatory properties of IL-12, without the morbidity and mortality associated with its systemic administration in clinical trials [25]. Although IL-12 has classically been described as an immunostimulatory cytokine that can mediate or intensify experimental GVHD [48,49], the timing and dosing of IL-12 is crucial in determining its effects. Thus, IL-12 inhibits GVHD when given early (1 hour before or 1 to 12 hours after bone marrow transplantation) but enhances GVHD when given late [50]. Our data suggest that RAPA-DCs are indeed an effective means to deliver IL-12 early after bone marrow transplantation and are compatible with the ability of IL-12 delivered with bone marrow transplantation to inhibit GVHD.

In the current studies, unstimulated RAPA-DCs failed to significantly prevent experimental GVHD. This is distinct from studies by Reichardt et al. [13], where splenic and bone marrow CD11c⁺ cells exposed to RAPA for 24 hours and infused with T cells after bone marrow transplantation were effective in prevention of GVHD. However, given the differences in preparation of RAPA-DCs between these studies and the lack of assessment by Reichardt et al. as to whether RAPA-DCs generated in this fashion overexpress IL-12, it is difficult to establish reasons for the differences in effectiveness between unstimulated RAPA-DCs in these two studies. Yet in these independent investigations, unstimulated syngeneic RAPA-DCs [13] or LPS-stimulated RAPA-DCs (the present report) delivered at the time of bone marrow transplantation have shown therapeutic benefit against GVHD. This is in contrast to CTR-DCs, which in both studies accelerated GVHD.

Previous work by Sykes and colleagues [22-24] demonstrated that GVHD protection through the administration of systemic IL-12 was IFN-γ dependent. In addition, IL-12 preserved important experimental GVL effects, also mediated through IFN-γ [23]. However, expansion to the clinical setting was halted because of excessive morbidity and mortality in phase I and II trials [25]. Both human and mouse DCs generated in or pulsed with RAPA express CCR7 at levels at or above CTR-DCs [9,13,51], and after their infusion, mouse RAPA-exposed DCs traffic to the secondary lymphoid tissue [13,26]. Thus, LPS-stimulated RAPA-DCs may enable targeted delivery of IL-12 to host lymphoid tissues without the toxic effects of IL-12 therapy as seen in clinical trials. We propose that increased IL-12 production may underlie the capacity of

Figure 6. Autologous IL-12hi RAPA-DC demonstrate low costimulatory molecule expression and inhibit acute GVHD. BALB/c CTR- and RAPA-DCs were generated and then analyzed for cell surface marker expression using flow cytometry. (A) Compared with equivalent CTR-DC groups, unstimulated RAPA- and LPS-exposed RAPA-DCs showed decreased surface expression (MFI) of IAd, CD86, and CD80. (B) BALB/c LPS-stimulated RAPA-DCs demonstrate increased IL-12 expression relative to LPS-stimulated CTR-DCs (CD11c⁺ IL-12hi population 67.3% versus 16.3%). (C) Lethally irradiated BALB/c recipients were given 5 × 10⁶ B6 bone marrow cells plus 1 × 10⁶ purified B6 T cells alone (GVHD control) or with 1 × 10⁶ BALB/c DCs (CTR-DC = LPS or RAPA-DC = LPS). Irradiated BALB/c mice injected with syngeneic BALB/c bone marrow (syngeneic) are also indicated. Although mice receiving CTR-DCs had survival comparable with the control GVHD group (without DCs) (median survival in days: GVHD, 17.5 days; CTR, 8 days; CTR-LPS, 11 days; all P = NS), IL-12hi RAPA-DCs significantly and markedly prolonged survival from GVHD (median survival in days: 38 days, P = .007).
envisioned that these advances in DC cellular therapy will phase I clinical testing in newly diagnosed cases of type 1 in vitro using clinical grade reagents and proven safe in initial human tolDCs have been generated and characterized. Clinical trials using cellular therapies for GVHD, including crucial GVL effects while abrogating experimental GVHD. 

GVHD remains a significant cause of post-transplant morbidity and mortality and limits the broader application of hematopoietic stem cell transplantation, such as to patients with nonmalignant diseases or without a matched related donor. Given the known role of DCs in the pathogenesis of GVHD [4] and the failure of therapies that target effector T cells to adequately prevent or treat GVHD, approaches that target DCs or DC cellular therapies are an attractive emerging strategy [4]. DCs are also required for full GVL effects (host > donor DC) [52-54], and, importantly, modulation of donor DC subsets [55,56] and the administration of tolDCs [57] has been shown to preserve these crucial effects while abrogating experimental GVHD. Clinical trials using cellular therapies for GVHD, including Treg and mesenchymal stem cells, are underway [4], and human tolDCs have been generated and characterized in vitro using clinical grade reagents and proven safe in initial phase I clinical testing in newly diagnosed cases of type 1 diabetes and rheumatoid arthritis [58-61]. It can be easily envisioned that these advances in DC cellular therapy will lead to future trials of tolDCs in GVHD. Further in vivo experimental studies of IL-12 RAPA-DCs are clearly indicated to both elucidate the role of cellular IL-12 in their prevention of GVHD and directly assess if GVL effects are preserved or potentiated.

ACKNOWLEDGMENTS 

Financial disclosure: Supported by National Institutes of Health (NIH) grants (R01AI67541 and R01AI60994 to A.W.T., R01HL93716 and R01GM63569 to M.Y.M., and K99/R00 HL97155 to H.R.T.) and the Pittsburgh Foundation (to M.Y.M.). B.R.R. is the recipient of an American Heart Association predoctoral fellowship (11PRE700020) and a nonconcurrent NIH T32 (AI74490) research training predoctoral fellowship.

Conflict of interest statement: A.W.T. is co-investor of US patents that concern generation of dendritic cells to promote transplant tolerance.

SUPPLEMENTARY DATA 

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.jbmt.2013.11.007.

REFERENCES 


